NOLA MOORE: Open Payments
NPI 1063529006 · MACON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$760 in 30 payments from 15 companies in 2025. Trend: 2023 $273 · 2024 $463 · 2025 $760
Food & beverage: $760
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $136 |
| AstraZeneca Pharmaceuticals LP | 7 | $118 |
| Otsuka America Pharmaceutical, Inc. | 1 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $99 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $47 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| ABBVIE INC. | 1 | $29 |
| Radius Health, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
Products named: REXULTI, Ozempic, CAPLYTA, BREZTRI, JOURNAVX, INGREZZA, Auvelity, AIRSUPRA.
Industry payments across MO — which companies pay providers there.
